NASDAQ · Biotechnology · USD

Skye Bioscience, Inc. (SKYE) Stock Analysis

Skye Bioscience, Inc. (SKYE) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

SKYE

$1.63

+$0.01 (+0.62%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare SKYE with… →

SKYE Key Statistics

As of Oct 21, 2026

Trading

Open: $1.65
Previous Close: $1.62
Day's Range: 1.59–1.65
52-Week Range: 1.50–13.28
Volume: 11.92K
Beta: 2.86

Valuation

Market Cap: $7.22M
P/E Ratio: unprofitable
EPS (ttm): −10.16

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$55.92M
Shares Outstanding: 4.43M
1-Year Return: −85.95%

Dividend and dates

Earnings Date: November 9, 2026estimated
Avg Volume: 89.93K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, SKYE closed at $1.63, −85.95% over 1 year.

Skye Bioscience, Inc. (SKYE) has a market capitalization of $7.22M.

In fiscal 2025, SKYE reported revenue of $0.00.

SKYE Stock Return by Calendar Year

Skye Bioscience, Inc. (SKYE) 10-year return: what $10,000 became

1 year: $10,000 $1,405; −85.95%
5 years: $10,000 $125; −98.75%
10 years: $10,000 $12; −99.88%

If you had invested $10,000 in Skye Bioscience, Inc. (SKYE) 10 years ago, at the close on October 21, 2016, it would have been worth $12 at the close on October 21, 2026: −99.88% in total, −48.97% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+163.16%−73.50%−72.83%

2016*2017201820192020202120222023202420252026*

Year	Return
2026 (partial year)	−72.83%
2025	−73.50%
2024	+4.04%
2023	−32.00%
2022	−69.23%
2021	+30.00%
2020	−69.47%
2019	−67.25%
2018	+163.16%
2017	−49.67%
2016 (partial year)	−42.80%

As of October 21, 2026.

SKYE Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$55.92M	—
2024	$0.00	−$26.57M	—
2023	$0.00	−$37.64M	—
2022	$0.00	−$19.48M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$58.16M	−$55.92M	—
2024	$0.00	—	−$36.43M	−$26.57M	—
2023	$0.00	—	−$13.67M	−$37.64M	—
2022	$0.00	—	−$12.11M	−$19.48M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Skye Bioscience, Inc. (SKYE) at $7.22M. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 2.

SKYE last closed at $1.63 on October 21, 2026. That is +$0.01 (+0.62%) against the previous close. The 52-week range on file runs from $1.50 to $13.28. The latest close sits 8.67% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $55.92M. Trailing earnings per share are −10.16.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The trailing one-year total return is −85.95%. Measured over 10 years, that is −48.97% a year compounded. The reported beta is 2.86. Daily returns over the trailing 10 years annualize to a volatility of 135.31%.

Growth & Income

The record shows no dividend for SKYE.

So far in 2026 the total return is −72.83%. Across the complete calendar years on file, 2018 returned +163.16% and 2025 returned −73.50%. Of the 9 complete calendar years on file, 3 finished higher.

Peer Comparison

Skye Bioscience, Inc. (SKYE) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Skye Bioscience, Inc.	SKYE	$7.22M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Skye Bioscience, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Skye Bioscience, Inc.

Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.

Visit website →